Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury

Xinqi Peng, Paul M. Hassoun, Saad Sammani, Bryan J. McVerry, Melissa J. Burne, Hamid Rabb, David Pearse, Rubin M. Tuder, Joe GN Garcia

Research output: Contribution to journalArticle

395 Citations (Scopus)

Abstract

Our prior in vitro studies indicate that sphingosine 1-phosphate (S1P), a phospholipid angiogenic factor, produces endothelial cell barrier enhancement through ligation of endothelial differentiation gene family receptors. We hypothesized that S1P may reduce the vascular leak associated with acute lung injury and found that S1P infusion produced a rapid and significant reduction in lung weight gain (more than 50%) in the isolated perfused murine lung. The effect of S1P was next assessed in a murine model of LPS-mediated microvascular permeability and inflammation with marked increases in parameters of lung injury at both 6 and 24 hours after intratracheal LPS. Each parameter assessed was significantly reduced by intravenous S1P (1 μM final) and in selected experiments by the S1P analogue FTY720 (0.1 mg/kg, intraperitoneally) delivered 1 hour after LPS. S1P produced an approximately 40-50% reduction in LPS-mediated extravasation of Evans blue dye albumin, bronchoalveolar lavage protein content, and lung tissue myeloperoxidase activity (reflecting phagocyte infiltration). Consistent with systemic barrier enhancement, S1P significantly decreased Evans blue dye albumin extravasation and myeloperoxidase content in renal tissues of LPS-treated mice. These studies indicate that S1P significantly decreases pulmonary/renal vascular leakage and inflammation in a murine model of LPS-mediated acute lung injury and may represent a novel therapeutic strategy for vascular barrier dysfunction.

Original languageEnglish (US)
Pages (from-to)1245-1251
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume169
Issue number11
StatePublished - Jun 1 2004
Externally publishedYes

Fingerprint

Lung Injury
Endotoxins
Blood Vessels
Lung
Evans Blue
Acute Lung Injury
Peroxidase
Albumins
Coloring Agents
Inflammation
Kidney
sphingosine 1-phosphate
Angiogenesis Inducing Agents
Capillary Permeability
Bronchoalveolar Lavage
Phagocytes
Weight Gain
Ligation
Phospholipids
Endothelial Cells

Keywords

  • Acute respiratory distress syndrome
  • Inflammation
  • Permeability
  • Sphingolipids

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. / Peng, Xinqi; Hassoun, Paul M.; Sammani, Saad; McVerry, Bryan J.; Burne, Melissa J.; Rabb, Hamid; Pearse, David; Tuder, Rubin M.; Garcia, Joe GN.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 169, No. 11, 01.06.2004, p. 1245-1251.

Research output: Contribution to journalArticle

Peng, X, Hassoun, PM, Sammani, S, McVerry, BJ, Burne, MJ, Rabb, H, Pearse, D, Tuder, RM & Garcia, JGN 2004, 'Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury', American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 11, pp. 1245-1251.
Peng, Xinqi ; Hassoun, Paul M. ; Sammani, Saad ; McVerry, Bryan J. ; Burne, Melissa J. ; Rabb, Hamid ; Pearse, David ; Tuder, Rubin M. ; Garcia, Joe GN. / Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. In: American Journal of Respiratory and Critical Care Medicine. 2004 ; Vol. 169, No. 11. pp. 1245-1251.
@article{8f50081720bb47afb6691651251d7ad8,
title = "Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury",
abstract = "Our prior in vitro studies indicate that sphingosine 1-phosphate (S1P), a phospholipid angiogenic factor, produces endothelial cell barrier enhancement through ligation of endothelial differentiation gene family receptors. We hypothesized that S1P may reduce the vascular leak associated with acute lung injury and found that S1P infusion produced a rapid and significant reduction in lung weight gain (more than 50{\%}) in the isolated perfused murine lung. The effect of S1P was next assessed in a murine model of LPS-mediated microvascular permeability and inflammation with marked increases in parameters of lung injury at both 6 and 24 hours after intratracheal LPS. Each parameter assessed was significantly reduced by intravenous S1P (1 μM final) and in selected experiments by the S1P analogue FTY720 (0.1 mg/kg, intraperitoneally) delivered 1 hour after LPS. S1P produced an approximately 40-50{\%} reduction in LPS-mediated extravasation of Evans blue dye albumin, bronchoalveolar lavage protein content, and lung tissue myeloperoxidase activity (reflecting phagocyte infiltration). Consistent with systemic barrier enhancement, S1P significantly decreased Evans blue dye albumin extravasation and myeloperoxidase content in renal tissues of LPS-treated mice. These studies indicate that S1P significantly decreases pulmonary/renal vascular leakage and inflammation in a murine model of LPS-mediated acute lung injury and may represent a novel therapeutic strategy for vascular barrier dysfunction.",
keywords = "Acute respiratory distress syndrome, Inflammation, Permeability, Sphingolipids",
author = "Xinqi Peng and Hassoun, {Paul M.} and Saad Sammani and McVerry, {Bryan J.} and Burne, {Melissa J.} and Hamid Rabb and David Pearse and Tuder, {Rubin M.} and Garcia, {Joe GN}",
year = "2004",
month = "6",
day = "1",
language = "English (US)",
volume = "169",
pages = "1245--1251",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "11",

}

TY - JOUR

T1 - Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury

AU - Peng, Xinqi

AU - Hassoun, Paul M.

AU - Sammani, Saad

AU - McVerry, Bryan J.

AU - Burne, Melissa J.

AU - Rabb, Hamid

AU - Pearse, David

AU - Tuder, Rubin M.

AU - Garcia, Joe GN

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Our prior in vitro studies indicate that sphingosine 1-phosphate (S1P), a phospholipid angiogenic factor, produces endothelial cell barrier enhancement through ligation of endothelial differentiation gene family receptors. We hypothesized that S1P may reduce the vascular leak associated with acute lung injury and found that S1P infusion produced a rapid and significant reduction in lung weight gain (more than 50%) in the isolated perfused murine lung. The effect of S1P was next assessed in a murine model of LPS-mediated microvascular permeability and inflammation with marked increases in parameters of lung injury at both 6 and 24 hours after intratracheal LPS. Each parameter assessed was significantly reduced by intravenous S1P (1 μM final) and in selected experiments by the S1P analogue FTY720 (0.1 mg/kg, intraperitoneally) delivered 1 hour after LPS. S1P produced an approximately 40-50% reduction in LPS-mediated extravasation of Evans blue dye albumin, bronchoalveolar lavage protein content, and lung tissue myeloperoxidase activity (reflecting phagocyte infiltration). Consistent with systemic barrier enhancement, S1P significantly decreased Evans blue dye albumin extravasation and myeloperoxidase content in renal tissues of LPS-treated mice. These studies indicate that S1P significantly decreases pulmonary/renal vascular leakage and inflammation in a murine model of LPS-mediated acute lung injury and may represent a novel therapeutic strategy for vascular barrier dysfunction.

AB - Our prior in vitro studies indicate that sphingosine 1-phosphate (S1P), a phospholipid angiogenic factor, produces endothelial cell barrier enhancement through ligation of endothelial differentiation gene family receptors. We hypothesized that S1P may reduce the vascular leak associated with acute lung injury and found that S1P infusion produced a rapid and significant reduction in lung weight gain (more than 50%) in the isolated perfused murine lung. The effect of S1P was next assessed in a murine model of LPS-mediated microvascular permeability and inflammation with marked increases in parameters of lung injury at both 6 and 24 hours after intratracheal LPS. Each parameter assessed was significantly reduced by intravenous S1P (1 μM final) and in selected experiments by the S1P analogue FTY720 (0.1 mg/kg, intraperitoneally) delivered 1 hour after LPS. S1P produced an approximately 40-50% reduction in LPS-mediated extravasation of Evans blue dye albumin, bronchoalveolar lavage protein content, and lung tissue myeloperoxidase activity (reflecting phagocyte infiltration). Consistent with systemic barrier enhancement, S1P significantly decreased Evans blue dye albumin extravasation and myeloperoxidase content in renal tissues of LPS-treated mice. These studies indicate that S1P significantly decreases pulmonary/renal vascular leakage and inflammation in a murine model of LPS-mediated acute lung injury and may represent a novel therapeutic strategy for vascular barrier dysfunction.

KW - Acute respiratory distress syndrome

KW - Inflammation

KW - Permeability

KW - Sphingolipids

UR - http://www.scopus.com/inward/record.url?scp=2542461296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542461296&partnerID=8YFLogxK

M3 - Article

VL - 169

SP - 1245

EP - 1251

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 11

ER -